Compare ELVA & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ELVA | CBIO |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | Canada | United States |
| Employees | N/A | 44 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.7M | 557.8M |
| IPO Year | 2021 | N/A |
| Metric | ELVA | CBIO |
|---|---|---|
| Price | $10.34 | $18.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $14.00 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 526.4K | 262.1K |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $34.68 | N/A |
| Revenue Next Year | $51.48 | $279.20 |
| P/E Ratio | $78.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.11 | $8.72 |
| 52 Week High | $12.78 | $27.41 |
| Indicator | ELVA | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 43.79 |
| Support Level | $8.51 | $17.48 |
| Resistance Level | $11.41 | $21.60 |
| Average True Range (ATR) | 0.80 | 1.94 |
| MACD | -0.08 | -0.32 |
| Stochastic Oscillator | 38.72 | 22.87 |
Electrovaya Inc is a technology-focused lithium-ion battery company engaged in designing, developing and manufacturing battery cells, modules and systems based on its proprietary Infinity Battery Technology, which provides high safety performance, long cycle life and durability. The Company supplies low-voltage and high-voltage battery systems for industrial and transportation markets, including material-handling equipment, robotic vehicles, electric buses and trucks, and energy-storage installations, and its products are suitable for mission-critical applications. it maintains an expanding intellectual-property portfolio, develops next-generation solid-state and hybrid solid-state battery technologies, and sells its products through OEM relationships, dealer networks and direct sales.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.